SynthesisJournal of neurology2026
Time- and threshold-dependent cerebrospinal fluid protein elevation and albuminocytologic dissociation in Guillain-Barré syndrome: a systematic review and meta-analysis.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrospinal fluid (CSF) protein elevation and albuminocytologic dissociation (ACD) are supportive features in Guillain-Barré syndrome (GBS), but their yield may depend on lumbar puncture timing and protein-threshold definition.
methodsWe registered the protocol in PROSPERO (CRD420261442200) and searched PubMed, Embase, Web of Science Core Collection, and Cochrane CENTRAL till 5th July 2026. Eligible studies reported extractable CSF protein elevation or ACD data in GBS-spectrum disorders. Records were screened and extracted independently. Random-effects logit models were used for pooled proportions.
resultsTwenty-four studies were included and 19 contributed quantitative data. In 12 main cohorts including 2966 patients, the pooled study-defined CSF protein elevation or ACD yield was 79.6% (95% confidence interval [CI] 70.4-86.5; I2 = 96.3%). Yield was lower during the first 0-1 days after onset (48.1%) and higher after the first week. Fixed 0.45 g/L thresholds gave a higher apparent yield than age-adjusted or age-dependent thresholds (69.5% vs 50.0%).
conclusionsCSF protein elevation and ACD are common supportive findings in GBS but their interpretation depends on timing and threshold definition. A normal CSF protein result during the first days after symptom onset does not exclude GBS. Conversely, a fixed low threshold may classify more results as abnormal than an age-adjusted reference limit. Timing and the threshold used should be reported when CSF findings are used to support the diagnosis.
trial registrationPROSPERO registration: CRD420261442200.
Indexed as
Identifiers
42616135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.